Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission
暂无分享,去创建一个
[1] R. Kaul,et al. Impact of asymptomatic Herpes simplex virus-2 infection on T cell phenotype and function in the foreskin , 2012, AIDS.
[2] L. van Damme,et al. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention , 2012, AIDS.
[3] J. Haberer,et al. Unraveling the divergent results of PrEP Trials for HIV Prevention , 2012 .
[4] Diarmaid J. Murphy,et al. Sustained Release of the CCR5 Inhibitors CMPD167 and Maraviroc from Vaginal Rings in Rhesus Macaques , 2012, Antimicrobial Agents and Chemotherapy.
[5] G. Shaw,et al. Mucosal Simian Immunodeficiency Virus Transmission in African Green Monkeys: Susceptibility to Infection Is Proportional to Target Cell Availability at Mucosal Sites , 2012, Journal of Virology.
[6] J. Baeten,et al. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence , 2012, Current opinion in infectious diseases.
[7] Jerome H. Kim,et al. Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys , 2011, Nature.
[8] John P. Moore,et al. Animal models for microbicide studies. , 2012, Current HIV research.
[9] John P. Moore,et al. Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[10] C. Cheng‐Mayer,et al. Delay of simian human immunodeficiency virus infection and control of viral replication in vaccinated macaques challenged in the presence of a topical microbicide , 2011, AIDS.
[11] K. Mansfield,et al. Durable Mucosal Simian Immunodeficiency Virus-Specific Effector Memory T Lymphocyte Responses Elicited by Recombinant Adenovirus Vectors in Rhesus Monkeys , 2011, Journal of Virology.
[12] S. Karim,et al. HIV prevention transformed: the new prevention research agenda , 2011, The Lancet.
[13] Matthew S. Lewis,et al. Profound early control of highly pathogenic SIV by an effector-memory T cell vaccine , 2011, Nature.
[14] M. Wainberg. AIDS: Drugs that prevent HIV infection , 2011, Nature.
[15] David V Glidden,et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.
[16] Thomas J. Smith,et al. Advances in microbicide vaginal rings. , 2010, Antiviral research.
[17] Lynn Morris,et al. Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.
[18] John P. Moore,et al. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. , 2010, The Journal of infectious diseases.
[19] J. Excler. HIV-vaccines: lessons learned and the way forward , 2010, Current opinion in HIV and AIDS.
[20] D. Burton,et al. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. , 2010, Current opinion in immunology.
[21] Brigitte E. Sanders-Beer,et al. Depo-Provera does not alter disease progression in SIVmac-infected female Chinese rhesus macaques. , 2010, AIDS research and human retroviruses.
[22] M. McChesney,et al. Depo-Provera® Treatment Does Not Abrogate Protection from Intravenous SIV Challenge in Female Macaques Immunized with an Attenuated AIDS Virus , 2010, PloS one.
[23] Ashley T. Haase,et al. Targeting early infection to prevent HIV-1 mucosal transmission , 2010, Nature.
[24] I. McGowan,et al. Advances in the Development of Microbicides for the Prevention of HIV Infection , 2010, Current infectious disease reports.
[25] B. Korber,et al. HIV-1 vaccine development after STEP. , 2010, Annual review of medicine.
[26] D. Montefiori,et al. Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys , 2008, Nature.
[27] John P. Moore,et al. Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249 , 2008, Proceedings of the National Academy of Sciences.
[28] R. MacArthur,et al. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] K. Mansfield,et al. Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D , 2007, Journal of Virology.
[30] K. Mansfield,et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity , 2006, Nature.
[31] John P. Moore,et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus–cell fusion , 2005, Nature.
[32] A. Haase. Perils at mucosal front lines for HIV and SIV and their hosts , 2005, Nature Reviews Immunology.
[33] Eun-Young Kim,et al. Propagation and Dissemination of Infection after Vaginal Transmission of Simian Immunodeficiency Virus , 2005, Journal of Virology.
[34] T. Quinn,et al. HIV/AIDS in Women: An Expanding Epidemic , 2005, Science.
[35] T. Merigan,et al. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. , 2004, The Journal of infectious diseases.
[36] R. Cheynier,et al. The infiltration kinetics of simian immunodeficiency virus-specific T cells drawn to sites of high antigenic stimulation determines local in vivo viral escape , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[37] C. Cheng‐Mayer,et al. Mucosal Transmission and Induction of Simian AIDS by CCR5-Specific Simian/Human Immunodeficiency Virus SHIVSF162P3 , 2001, Journal of Virology.
[38] D Wick,et al. Early HIV infection in vivo: branching-process model for studying timing of immune responses and drug therapy. , 2000, Mathematical biosciences.
[39] J. Lifson,et al. Effectiveness of Postinoculation (R)-9-(2-Phosphonylmethoxypropyl)Adenine Treatment for Prevention of Persistent Simian Immunodeficiency Virus SIVmne Infection Depends Critically on Timing of Initiation and Duration of Treatment , 1998, Journal of Virology.
[40] D. Ho,et al. Progesterone implants enhance SIV vaginal transmission and early virus load , 1996, Nature Medicine.